Listen on the go
CORRECT!
Next question
touchOPHTHALMOLOGY touchOPHTHALMOLOGY
Anterior Segment, Refractive Surgery

John Ladas, ESCRS 2019 – AI approach to IOL power calculation

Share this Video
Copy Link
Published Online: Sep 23rd 2019

John Ladas (Maryland Eye Consultants) talks about the challenges and recent studies on an artificial intelligence approach to IOL power calculations at ESCRS 2019.

Questions:
1. What are the limitations of current methods of intraocular lens (IOL) power calculation?
2. Could you tell us a little about the artificial intelligence (AI) approach to IOL power calculation?
3. What are the major challenges to using AI algorithms and how may they be overcome?
4. What clinical data supports the use of AI models?
5. What are the key take home messages of your presentation?

Support: No funding was received for the production of this video.
Disclosures: John Ladas is the founder of Advanced Euclidean Solutions.

Related Videos In Refractive Surgery
Cataract Surgery, Refractive Surgery
Developed by Touch
Mitchell A Jackson, Hawaiian Eye and Retina 2023: Intraocular lens exchange – surgical pearls
Watch Time: 7:07 mins

It was a pleasure to have the opportunity to meet with Dr Mitchell A Jackson (Jacksoneye, Lake Villa, IL, USA)  who shared surgical pearls from his presentation, on successful IOL exchange with an open capsule. Questions:     What risks are associated with intraocular lens (IOL) exchange with an open capsule? (0:19)     What […]

Cataract Surgery, Refractive Surgery
Developed by Touch
Mitchell A Jackson, Hawaiian Eye and Retina 2023: Challenges for ophthalmic surgeons
Watch Time: 3:45 mins

We were delighted to speak with Dr Mitchell A Jackson (Jacksoneye, Lake Villa, IL, USA) on his views about the main challenges faced by ophthalmic surgeons today, and common reasons for IOL exchange. Questions: 1. What are the biggest challenges facing ophthalmologic surgeons today? (0:19) 2. What are the most common reasons for intraocular lens […]

Refractive Surgery
Pilocarpine hydrochloride ophthalmic solution 1.25%: An innovative prescription eye drop for the treatment of presbyopia
Watch Time: 5:02

Video abstract delivered by Dr Selina McGee (BeSpoke Vision, Edmond, OK, USA) for the article: McGee S, Waring GO, Pilocarpine hydrochloride ophthalmic solution 1.25%: an innovative prescription eye drop for the treatment of presbyopia. touchREVIEWS in Ophthalmology. 2022;16(2):54–62 DOI: https://doi.org/10.17925

Trending In Refractive Surgery:

Mitchell A Jackson, Hawaiian Eye and Retina 2023: Intraocular lens exchange – surgical pearls
Cataract Surgery, Refractive Surgery
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72